USES: This medication is used along with a non-drug program (including diet changes) to treat cholesterol and lipid disorders.

Similar documents
Molsidomine 2mg / 4mg Tablets

Frequently Asked Questions (FAQs) About the LIPITOR Savings Program*

XEOMIN (incobotulinumtoxina) PATIENT SAVINGS PROGRAM

Georgia Foot & Ankle

Tracy Blum Physical Therapy, Inc NEW PATIENT REGISTRATION FORM PATIENT INFORMATION. Last Name: First Name: Middle Initial: Social Security no.

Patient Registration Form

Prominence Health Plan. Pharmacy Benefits Guide Program Overview

Prescription Drug Rider

Bellingham Arthritis & Rheumatology Center. 470 Birchwood Avenue, Suite C, Bellingham, WA (P) (F)

Patients who are running 20 minutes late for his/her scheduled appointment will be rescheduled to the next available appointment/ day.

SBCFF Modified Rx 10/30/45 Prescription Drug Benefits

PATIENT INFORMATION SHEET

Date of Birth (MM/DD/YYYY) / / Age Social Security Number - - Marital Status . Cell Phone. Work Number Pharmacy Number

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Puma Biotechnology Reports Third Quarter 2018 Financial Results

Patient Information Last Name First Name Middle Initial

Name: (Last) (First) (M.I.) (Nick Name) Address: City: State: Zip: Address:

PATIENT REGISTRATION FORM

Has a family member been a patient in our office? Yes No

NAME AND PHONE NUMBER OF PHARMACY:

ERIC ROCKMORE, DPM, FACFAS

Name Relationship Phone #

PRIMARY INSURANCE TO FILE SECONDARY INSURANCE TO FILE

Hikma Pharmaceuticals PLC

Parent/Guardian Name: Social Security #: Male / Female: Date of Birth: / / Home Phone: Mobile Phone: Work Phone: Street Address: City: State: Zip:

Randall Stettler, D.D.S, Inc 5565 Grossmont Center Dr, Building 1 Suite 129, La Mesa, CA (619)

PATIENT NAME: SEX: M / F DATE OF BIRTH: AGE: S.S# ADDRESS: Street: City: State: Zip Code:

PATIENT REGISTRATION FORM Account #:

Endocrinology of the Rockies, PC. PATIENT REGISTRATION FORM E. 9th Ave. Ste. 245, Denver, CO 80220

New Patient Packet Please print and complete the following 6 pages. Bring the completed forms to your scheduled appointment. Thank you!

Placer Oral & Maxillofacial Surgery Nicholas Rotas, DDS, Inc.

Rx Benefits. Generic $10.00 Brand name formulary drug $30.00

Patient Information. Primary Care Physician: Last Name: First Name: MI: Address: City/ST/Zip code: Home Phone :( ) Cell Phone: ( ) Leave Message

OVERVIEW PROCESS SERVICES HARVONI. Simply on Your Side. Please see full Prescribing Information, including Patient Information.

PATIENT INFORMATION PRIMARY INSURANCE INFORMATION

appointment checklist

Patient Information Sheet. Spouse Information. Emergency Contact Information. Referral. Insurance Information

PATIENT INFORMATION FORM - DIABETES

The Center for Hospital Finance and Management

Mailing Address City State Zip Code. Employer City State Zip Code. How did you hear about us? Circle one

ERIC ROCKMORE, DPM, FACFAS STEPHANIE HORLING, DPM, FACFAS

Georgia Knotek D.D.S. Personalized Dental Care

SUMON NANDI, MD NEW ENGLAND BAPTIST HOSPITAL 125 PARKER HILL AVENUE FOGG BUILDING, SUITE 501 BOSTON, MA 02120

Kruse Park Chiropractic Clinic

12319 N Mopac Expy, Bldg C, Suite #300, Austin, Tx (512) NEW PATIENT INFORMATION P L E A S E P R I N T

Thomas Yoon Dental Patient Information. Health Information

Moving from Pediatric to Adult Care: Prescription Medicines, Supplies, and Equipment

Family Medicine Center of the Bitterroot, P.C.

PATIENT REGISTRATION FORM

Christine LaComb, RN, FNP-C th Street Suite B Groves, TX (409) Phone (409) Fax

Twin Cities Pain Clinic Phone: (952) Burnsville Edina Maple Grove Woodbury Fax: (952)

Arizona Center for Aesthetic Plastic Surgery Steven H. Turkeltaub, M.D., P.C. Certified, American Board of Plastic Surgery

Patient Registration Form

VASCULAR HEART & LUNG ASSOCIATES

ACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS. Supporting employees and building sustainable drug plans...together

Prominence Health Plan. Pharmacy Benefits Guide Program Overview

Name (Last, First, MI): Date of Birth: / /

Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

Prefix Last First Middle Suffix. Maiden Gender SSN Marital Status Date of Birth

Welcome to West County Vision Center

Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - Pharmacy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K

Eye Doctor, MD, P.C.

Clinical Policy: Brand Name Override Reference Number: CP.PMN.22 Effective Date: Last Review Date: 02.18

Subject: Pharmacy Services & Formulary Management (Page 1 of 5)

PLEASE FILL IN ALL INFORMATION COMPLETELY CITY STATE ZIP HOME PHONE # CELL # DATE OF BIRTH: YOUR EMPLOYER PHONE # HOW DID YOU HEAR ABOUT US?

Welcome. Patient Name: Social Security #: (Last name) (First name) (Middle Initial) Street Address City State Zip

GARRAMONE PLASTIC SURGERY (239)

Your Summary of Benefits PPO Copay Plans

Name: Date of Birth: Sex: Language: Race: Ethnicity: Home Address: City: State: Zip: Home Phone #: Marital Status: SS #:

William Salcedo, D.P.M. Diplomat American Board of Podiatric Surgery Board Certified in Foot Surgery Se Habla Español

PATIENT QUESTIONNAIRE DATE OF VISIT: Pg. 1

Gary W. White, M.D. Dean A. Cione, M.D. Jeremy S. Carrasco, M.D. Ramsey A. Stone, M.D

Arizona Retina Associates

OFFICE VISIT CHECKLIST

HIPAA PATIENT CONSENT FORM

Please complete entire form

HEALTH HISTORY. Physician s Name Phone# Date of Last Visit

Christos Vasakiris, D.C.,D.A.C.A.N. 350 West Montauk Highway Lindenhurst, N.Y, 11757

Your Summary of Benefits PPO GenRx Plans

Palm Valley Oral and Maxillofacial Surgery

INFECTIOUS DISEASE SERVICES OF GEORGIA, P.C. ROSWELL CUMMING JOHNS CREEK REGISTRATION FORM

CENTER CITY DERMATOLOGY STEPHEN HESS, M.D., Ph.D. MEDICAL HISTORY

Name: First MI Last. Birthdate: / / Age: Social Security #:

PATIENT INFORMATION NOTICE OF PRIVACY POLICY PATIENT ACKNOWLEDGEMENT

Get the most out of your pharmacy benefit.

Chief Complaint Form: Patient Name: Age: DOB: Occupation: Employer: Referring Physician: Town: Primary Care Physician: Town: Y N

Address: How did you hear about us? Name: Date of Birth: / / Address: City: State: Zip code: Phone Number: HOME - - WORK - - CELL - - EMPLOYER:

Princeton University Prescription Drug Plan Summary Plan Description

Patient Information Please print legibly and complete all information. If a prompt does not apply, please draw a line through the space provided.

PATIENT INFORMATION DATE NAME PREFERRED NAME: LAST FIRST MI

CENTRAL FLORIDA ORAL & MAXILLOFACIAL SURGERY, PA PATIENT REGISTRATION Date: PATIENT INFORMATION

GROUP INSURANCE EVIDENCE OF INSURABILITY FORM. SECTION 1: EMPLOYER INFORMATION (to be completed by authorized Plan Administrator):

Stat or Routine Exam / Procedure: Chart # Date of Exam: Age: Sex: Date of Birth: Patient s Name: Referring Physician:

PAYMENT POLICY: Payment or partial payment is required on the day of visit.

Haroon Rehman, MD 3200 Talon Drive. Suite 300 Richardson, TX Phone: Fax: Address: City: ST: ZIP:

Roberta June Guibord D.O., Inc. Patient Information Sheet

West Houston Infectious Disease Associates. Address: Number Street Apt. No. City State Zip. Home Phone: Cell: Work:

In case of emergency, please contact Phone # Relation. Name Soc. Sec.# Birth Date Age Phone # Name Relation Soc. Sec.# Birth Date

MORE MD Patient Information

Transcription:

Fenofibrate Capsule, Fenofibrate Capsule India, Fenofibrate Capsule manufacturers India, side effects Fenofibrate Capsule manufacturers, Taj Pharma India, Fenofibrate Capsule overdose, Fenofibrate Capsule drug, Fenofibrate Capsule composition, Manufacturing Pharmaceutical, Fenofibrate Capsule brand, contains, Fenofibrate Capsule India, Fenofibrate Capsule side effects, Fenofibrate Capsule use, Fenofibrate Capsule overdose, Fenofibrate Capsule drug, Fenofibrate Capsule composition, Fenofibrate Capsule Manufacturing, Pharmaceutical manufacturers, Fenofibrate Capsule contains, Fenofibrate Capsule Manufacturing, Fenofibrate Capsule Pharmaceutical manufacturers, Fenofibrate Capsule side effects, Fenofibrate Capsule use Fenofibrate Capsule,Fenofibrate Capsule overdose, Fenofibrate Capsule drug Fenofibrate Capsule, composition Fenofibrate Capsule, Pharmaceuticals, Allopathic Products, Manufacturer exporter, Supplier Fenofibrate Capsule India formulations, manufacturers Taj Products Pharmaceuticals Products, Manufacturer exporter, Supplier india formulations, Fenofibrate Capsule tablets, medicines injections, (Fenofibrate Capsule) Tablets, Pharmaceutical Product, Fenofibrate Capsule tablets, Manufacturing pharmaceuticals manufacturing pharma Fenofibrate Capsule tablets pharmacy Tablets pharmaceutical drugs, pharmaceutical, formulations Fenofibrate Capsule tablets, active pharmaceutical ingredients, manufacturer pharmaceutical, packaging Fenofibrate Capsule tablets, pharmaceutical drugs, global pharmaceutical Fenofibrate Capsule tablets, capsules, pharmaceutical raw materials, pharmaceutical drug, Pharmaceuticals manufacturer, Pharmacological Products Fenofibrate Capsule, tablets Tablets, Exporter India, Capsules Injections, manufacturing Pharmaceuticals, Manufacturer India, Tablets Fenofibrate Capsule, Tablets manufacturers Fenofibrate Capsule, Tablets Manufacturing, Fenofibrate Capsule tablets, Pharmaceutical manufacturers Taj Pharma India Generics Fenofibrate Capsule Each hard gelatin capsule contains: Fenofibrate BP..200 mg Excipients Approved Colour used in empty gelatin shell Excipients..Q.S. USES: This medication is used along with a non-drug program (including diet changes) to treat cholesterol and lipid disorders. HOW TO USE: This medication may be taken with or without food. Dosage is adjusted based on your condition and response. The maximum daily dose is 200 mg. Separate doses of this drug and any bile acid resin drug (e.g., colestipol or cholestyramine) by at least 4 hours. Full effects of this drug may take up to 3 months to occur. SIDE EFFECTS: Upset stomach, constipation, headache, dizziness or trouble sleeping may occur. If these effects persist or worsen, notify your doctor promptly. Report promptly: muscle pain, tenderness, weakness, fever. Very unlikely but report promptly: decreased sexual drive, yellowing eyes or skin, stomach pain. In the unlikely event you have a serious allergic reaction to this drug, seek immediate medical attention. Symptoms of a serious allergic reaction include: rash, itching, swelling, severe dizziness, trouble breathing. If you notice other effects not listed above, contact your doctor or pharmacist. PRECAUTIONS: Tell your doctor your medical history, including: any allergies, diabetes, liver and/or kidney disease, gallbladder disease, low thyroid (hypothyroidism), muscle disorders. In the U.S. - The manufacturer states this medication should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor. In Canada - The manufacturer states this medication must not be used during pregnancy. If you become pregnant or think you may be pregnant, inform your doctor immediately. Women of childbearing age should use an effective form of birth control. Stop using this drug for several months before planning a pregnancy. It is not known whether this drug is excreted into breast milk. Breast-feeding while using this drug is not recommended. Consult your doctor before breastfeeding. DRUG INTERACTIONS: Use caution if the following drugs are combined with fenofibrate because serious side effects such as muscle injury (myopathy) infrequently could occur: "statins" (e.g., lovastatin, atorvastatin), high-dose niacin (1 gram or more per day). Tell your doctor of all nonprescription and prescription medication you may use, especially: "blood thinners" (e.g., warfarin), cyclosporine, MAO Inhibitors (e.g., selegiline, furazolidone, tranylcypromine, phenelzine, moclobemide), certain diabetic medicine (sulfonylureas such as glipizide; and insulin), estrogens/birth control pills. Do not start or stop any medicine without doctor or pharmacist approval. OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. Copyright 2012 Taj Pharma Group (India),. All rights reserved. Note:-We are committed to helping you find the right answers to your questions and concerns. However, this Report is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider. Active P h a r m a c e u t i c a l I n g r e d i e n t s m a n u f a c t u r e r, e x p o r t e r, d r u g i n g r e d i e n t s, p h a r m a c e u t i c a l s, I n d i a Additionally, contact information on this Report cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to

Generics Fenofibrate Capsule For Information about Generic Medicines : genericmedicines@tajpharma.com Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions from the most common to the most challenging for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India. Information for Health Care Professionals *** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited). Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. Copyright 2012 Taj Pharma Group (India),. All rights reserved. Note:-We are committed to helping you find the right answers to your questions and concerns. However, this Report is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider. Active P h a r m a c e u t i c a l I n g r e d i e n t s m a n u f a c t u r e r, e x p o r t e r, d r u g i n g r e d i e n t s, p h a r m a c e u t i c a l s, I n d i a Additionally, contact information on this Report cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to

DISLAIMER THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION. NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. This document includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, expected, plan, goal believe, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents. Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. 3

About Taj Pharmaceutical Limited Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufacturers pharmaceutical formulations and API for India and other countries of world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India. According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries. www.tajpharma.com The company medicines are present in France, Georgia, Egypt and CIF countries. Taj Pharmaceuticals Limited Working For Healthier World INDIA Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website. The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forwardlooking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements. 10

Further Details Please Visit: www.tajpharma.com The contents and design of this website, including Authority logos, are the property of the Taj Pharmaceuticals Limited India, and are protected under copyright law and international treaty. All rights reserved. Except under the conditions described in the Copyright Act 1968 and subsequent amendments, no part of this website may be reproduced or communicated by any process without prior permission in writing from Copyright 2004-2011 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labeling in different countries. The product information provided in this site is intended only for the residents of India. 11

2024 © financedocbox.com Privacy Policy | Terms of Service | Feedback